OCI develops therapies for leukaemia based on CAR–T.
OneChain Immunotherapeutics has raised $7.3M in total funding. The most recent round was Seed. The last funding was announced in June 2023.
OneChain Immunotherapeutics's investors include Centre for the Development of Industrial Technology (CDTI), Invivo Capital Partners, Josep Carreras Leukaemia Research Institute, Nara Capital, Clave Capital.
OneChain Immunotherapeutics is headquartered in Barcelona, Spain.
OCI develops therapies for leukaemia based on CAR–T.
OneChain Immunotherapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OneChain Immunotherapeutics — Funding & Investors." VCBacked, June 22, 2023, https://www.vcbacked.co/company/onechain-immunotherapeutics. Accessed July 20, 2026.
VCBacked. (2023). OneChain Immunotherapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/onechain-immunotherapeutics
{{cite web |title=OneChain Immunotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/onechain-immunotherapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated